All the benefits of VAXXITEK® HVT+IBD, now designed with ND protection.
Brand Insights from Boehringer Ingelheim
Why has Boehringer Ingelheim developed an IBD + ND vector vaccine?
Newcastle Disease (ND) is a viral disease of chickens caused by the Avulovirus (Paramyxoviridae) that causes respiratory, digestive, nervous, and reproductive symptoms associated with a high mortality rate and a high economic impact1. Boehringer Ingelheim Animal Health launched VAXXITEK® HVT+IBD, the first ever HVT based vectored vaccine in 2006. When HVT bivalent vector vaccines are combined with other HVT recombinant vaccines, the combination was reported to reduce the efficacy of one or both vaccines. Therefore, in 2019, Boehringer Ingelheim Animal Health launched VAXXITEK® HVT+IBD+ND, to offer protection in one shot from Newcastle disease, Marek’s disease, and infectious bursal disease (classic and variant types). With this innovation, Boehringer Ingelheim is able to improve the vaccination convenience for the poultry producers while keeping the benefits of the immune foundation brought by VAXXITEK®’s construct.
What do I need to know about the Newcastle Disease (ND)?
ND can be diagnosed based on history, clinical signs, and lesions:
What are the levels of protection and safety of VAXXITEK® HVT+IBD+ND?
VAXXITEK® HVT+IBD+ND is approved to provide early onset of immunity against NDV from day 28.
VAXXITEK® HVT+IBD+ND has been designed to provide rapid and long-lasting protection2,3,4,5,6 against Newcastle disease in association with a live ND vaccines.
Additional clinical studies showed that ND clinical protection starts from D21
Read the full article in Poultry Trends November issue.